US OptionsDetailed Quotes
HUMA241220P2500
- 0.10
- -0.05-33.33%
15min DelayClose Dec 3 16:00 ET
0.15High0.10Low
0.15Open0.15Pre Close2.86K Volume4.32K Open Interest2.50Strike Price38.23KTurnover240.33%IV43.53%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0971Delta0.0792Gamma34.00Leverage Ratio-0.0112Theta-0.0002Rho-3.30Eff Leverage0.0016Vega
Humacyte Stock Discussion
🏄🏼♂️🏄🏼♂️🏄🏼♂️
🥱🥱🥱😴😴😴
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
Benzinga· 3 mins ago
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
what happened? the earnings suck but now the stock is rising
No comment yet